FDA Clears Organogenesis' Next Generation PuraPly Surgical Solution

• Organogenesis Holdings Inc (NASDAQ: ORGO) has received the FDA 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio.

• Of the U.S.'s 40 to 50 million surgeries each year, up to 28% of surgical sites must be left open to heal.

• Related: Organogenesis' Q2 Operating Income Fell 50%, Lowers Annual Guidance.

• Organogenesis developed PuraPly MZ, a powder designed to support wound healing in deep, tunneling, and complex wounds to support clinicians and patients with these complex post-surgical wounds.

• PuraPly MZ consists of native structured collagen designed to allow for maximum coverage and maintenance of optimal contact with the contours of the wound surface to support healing.

• Price Action: ORGO shares are up 2.44% at $4.83 during the market session on the last check Monday.

See more from Benzinga

• Organogenesis' Q2 Operating Income Fell 50%, Lowers Annual Guidance

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.